vs
Side-by-side financial comparison of Guardant Health, Inc. (GH) and ROGERS CORP (ROG). Click either name above to swap in a different company.
Guardant Health, Inc. is the larger business by last-quarter revenue ($281.3M vs $200.5M, roughly 1.4× ROGERS CORP). ROGERS CORP runs the higher net margin — 2.2% vs -45.7%, a 47.9% gap on every dollar of revenue. On growth, Guardant Health, Inc. posted the faster year-over-year revenue change (39.4% vs 5.2%). ROGERS CORP produced more free cash flow last quarter ($1.1M vs $-54.2M). Over the past eight quarters, Guardant Health, Inc.'s revenue compounded faster (29.2% CAGR vs -3.3%).
Guardant Health, Inc. is an American biotechnology company based in Palo Alto, California. Co-founders Helmy Eltoukhy and AmirAli Talasaz serve as co-chief executive officers.
Rogers Corporation is a specialty engineered materials company headquartered in Chandler, Arizona.
GH vs ROG — Head-to-Head
Income Statement — Q4 FY2025 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $281.3M | $200.5M |
| Net Profit | $-128.5M | $4.5M |
| Gross Margin | 64.6% | 32.2% |
| Operating Margin | -43.0% | — |
| Net Margin | -45.7% | 2.2% |
| Revenue YoY | 39.4% | 5.2% |
| Net Profit YoY | -15.8% | 421.4% |
| EPS (diluted) | $-1.01 | $0.25 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $200.5M | ||
| Q4 25 | $281.3M | $201.5M | ||
| Q3 25 | $265.2M | $216.0M | ||
| Q2 25 | $232.1M | $202.8M | ||
| Q1 25 | $203.5M | $190.5M | ||
| Q4 24 | $201.8M | $192.2M | ||
| Q3 24 | $191.5M | $210.3M | ||
| Q2 24 | $177.2M | $214.2M |
| Q1 26 | — | $4.5M | ||
| Q4 25 | $-128.5M | $4.6M | ||
| Q3 25 | $-92.7M | $8.6M | ||
| Q2 25 | $-99.9M | $-73.6M | ||
| Q1 25 | $-95.2M | $-1.4M | ||
| Q4 24 | $-111.0M | $-500.0K | ||
| Q3 24 | $-107.8M | $10.7M | ||
| Q2 24 | $-102.6M | $8.1M |
| Q1 26 | — | 32.2% | ||
| Q4 25 | 64.6% | 31.5% | ||
| Q3 25 | 64.7% | 33.5% | ||
| Q2 25 | 65.0% | 31.6% | ||
| Q1 25 | 63.3% | 29.9% | ||
| Q4 24 | 61.6% | 32.1% | ||
| Q3 24 | 61.1% | 35.2% | ||
| Q2 24 | 59.1% | 34.1% |
| Q1 26 | — | — | ||
| Q4 25 | -43.0% | 3.5% | ||
| Q3 25 | -37.3% | 7.3% | ||
| Q2 25 | -45.9% | -33.3% | ||
| Q1 25 | -54.6% | -0.2% | ||
| Q4 24 | -62.4% | -6.6% | ||
| Q3 24 | -61.3% | 6.9% | ||
| Q2 24 | -56.8% | 5.3% |
| Q1 26 | — | 2.2% | ||
| Q4 25 | -45.7% | 2.3% | ||
| Q3 25 | -35.0% | 4.0% | ||
| Q2 25 | -43.0% | -36.3% | ||
| Q1 25 | -46.8% | -0.7% | ||
| Q4 24 | -55.0% | -0.3% | ||
| Q3 24 | -56.3% | 5.1% | ||
| Q2 24 | -57.9% | 3.8% |
| Q1 26 | — | $0.25 | ||
| Q4 25 | $-1.01 | $0.20 | ||
| Q3 25 | $-0.74 | $0.48 | ||
| Q2 25 | $-0.80 | $-4.00 | ||
| Q1 25 | $-0.77 | $-0.08 | ||
| Q4 24 | $-0.90 | $-0.04 | ||
| Q3 24 | $-0.88 | $0.58 | ||
| Q2 24 | $-0.84 | $0.44 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $378.2M | $195.8M |
| Total DebtLower is stronger | $1.5B | — |
| Stockholders' EquityBook value | $-99.3M | $1.2B |
| Total Assets | $2.0B | $1.4B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $195.8M | ||
| Q4 25 | $378.2M | $197.0M | ||
| Q3 25 | $580.0M | $167.8M | ||
| Q2 25 | $629.1M | $157.2M | ||
| Q1 25 | $698.6M | $175.6M | ||
| Q4 24 | $525.5M | $159.8M | ||
| Q3 24 | $585.0M | $146.4M | ||
| Q2 24 | $933.7M | $119.9M |
| Q1 26 | — | — | ||
| Q4 25 | $1.5B | — | ||
| Q3 25 | $1.1B | — | ||
| Q2 25 | $1.1B | — | ||
| Q1 25 | $1.1B | — | ||
| Q4 24 | $1.1B | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | $1.2B | ||
| Q4 25 | $-99.3M | $1.2B | ||
| Q3 25 | $-354.5M | $1.2B | ||
| Q2 25 | $-305.5M | $1.2B | ||
| Q1 25 | $-250.8M | $1.3B | ||
| Q4 24 | $-139.6M | $1.3B | ||
| Q3 24 | $-60.1M | $1.3B | ||
| Q2 24 | $-1.6M | $1.3B |
| Q1 26 | — | $1.4B | ||
| Q4 25 | $2.0B | $1.4B | ||
| Q3 25 | $1.3B | $1.4B | ||
| Q2 25 | $1.3B | $1.5B | ||
| Q1 25 | $1.3B | $1.5B | ||
| Q4 24 | $1.5B | $1.5B | ||
| Q3 24 | $1.5B | $1.5B | ||
| Q2 24 | $1.6B | $1.5B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-26.4M | $5.8M |
| Free Cash FlowOCF − Capex | $-54.2M | $1.1M |
| FCF MarginFCF / Revenue | -19.3% | 0.5% |
| Capex IntensityCapex / Revenue | 9.9% | 2.3% |
| Cash ConversionOCF / Net Profit | — | 1.29× |
| TTM Free Cash FlowTrailing 4 quarters | $-233.1M | $70.1M |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $5.8M | ||
| Q4 25 | $-26.4M | $46.9M | ||
| Q3 25 | $-35.4M | $28.9M | ||
| Q2 25 | $-60.3M | $13.7M | ||
| Q1 25 | $-62.7M | $11.7M | ||
| Q4 24 | $-64.5M | $33.7M | ||
| Q3 24 | $-51.1M | $42.4M | ||
| Q2 24 | $-94.0M | $22.9M |
| Q1 26 | — | $1.1M | ||
| Q4 25 | $-54.2M | $42.2M | ||
| Q3 25 | $-45.8M | $21.2M | ||
| Q2 25 | $-65.9M | $5.6M | ||
| Q1 25 | $-67.1M | $2.1M | ||
| Q4 24 | $-83.4M | $18.3M | ||
| Q3 24 | $-55.3M | $25.2M | ||
| Q2 24 | $-99.1M | $8.8M |
| Q1 26 | — | 0.5% | ||
| Q4 25 | -19.3% | 20.9% | ||
| Q3 25 | -17.3% | 9.8% | ||
| Q2 25 | -28.4% | 2.8% | ||
| Q1 25 | -33.0% | 1.1% | ||
| Q4 24 | -41.3% | 9.5% | ||
| Q3 24 | -28.9% | 12.0% | ||
| Q2 24 | -55.9% | 4.1% |
| Q1 26 | — | 2.3% | ||
| Q4 25 | 9.9% | 2.3% | ||
| Q3 25 | 3.9% | 3.6% | ||
| Q2 25 | 2.4% | 4.0% | ||
| Q1 25 | 2.2% | 5.0% | ||
| Q4 24 | 9.4% | 8.0% | ||
| Q3 24 | 2.2% | 8.2% | ||
| Q2 24 | 2.9% | 6.6% |
| Q1 26 | — | 1.29× | ||
| Q4 25 | — | 10.20× | ||
| Q3 25 | — | 3.36× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | 3.96× | ||
| Q2 24 | — | 2.83× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
GH
| Oncology | $189.9M | 68% |
| Biopharma Data | $54.0M | 19% |
| Screening | $35.1M | 12% |
| Licensing Other | $2.2M | 1% |
ROG
Segment breakdown not available.
